Immuneoncia Therapeutics Inc., a joint venture between South Korea’s Yuhan Corp. and San Diego-based Sorrento Therapeutics Inc., is looking to list on the Korea Exchange, having recently passed local technology evaluation.
Immuneoncia Therapeutics Inc., a joint venture between South Korea’s Yuhan Corp. and San Diego-based Sorrento Therapeutics Inc., is looking to list on the Korea Exchange, having recently passed local technology evaluation.
Sorrento Therapeutics Inc. has divulged antibody-drug conjugates comprising antibodies targeting HER2 covalently linked to exatecan through a linker. They are reported to be useful for the treatment of cancer.
Sorrento Therapeutics Inc. has published data on the identification, in vitro binding and neutralizing activity of a novel monoclonal antibody (MAb), STI-5041, against the SARS-CoV-2 WA-1 strain as well as the alpha and beta variants from their G-MAB library screening.
Levena Biopharma Co. Ltd. and Sorrento Therapeutics Inc. have synthesized antibody-drug conjugates consisting of auristatin analogues covalently linked to monoclonal antibody targeting B-cell maturation protein (BCMA) through a linker.
Sorrento Therapeutics Inc.’s majority-owned subsidiary, Scilex Holding Co., and antibody drug developer Apexigen Inc. both announced plans late this week to go public via mergers with special purpose acquisition companies (SPACs), suggesting that, despite current market conditions, SPACs are still considered a viable option for firms seeking cash and access to public markets.
VANCOUVER – Sorrento Therapeutics Inc., which is working to build a comprehensive lineup of COVID-19 products, has in-licensed a self-contained test for SARS-CoV-2 that may produce accurate results in half an hour.
With the green light for a phase II trial to test a new drug to tackle some of the impacts of COVID-19, clinical-stage antibody developer Sorrento Therapeutics Inc. is going all in on the COVID-19 business. The company is now developing three therapeutic products, one diagnostic and a vaccine.
With the green light for a phase II trial to test a new drug to tackle some of the impacts of COVID-19, clinical-stage antibody developer Sorrento Therapeutics Inc. is going all in on the COVID-19 business.
With some positive early data for an antibody to block the COVID-19 virus, Sorrento Therapeutics Inc. is now looking to test a product in a few dozen intensive care patients by the end of July or early August and move into a much broader pool of patients by October.